ArticleDermatology and therapy2026
Psychiatric and Psychological Approach in Patients with Atopic Dermatitis, Hidradenitis Suppurativa and Psoriasis: A Propensity-Matched Real-World Cohort Study.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChronic inflammatory dermatoses-atopic dermatitis (AD), hidradenitis suppurativa (HS), and psoriasis (PsO)-are linked to elevated rates of psychosocial consequences. Beyond controlling cutaneous inflammation, contemporary care should address psychosocial well-being, yet real-world evidence on psychiatric and psychological service use in these diseases is limited. To quantify the prevalence and risk of psychiatric evaluation, psychotherapy, and psychiatric pharmacotherapy among adults with AD, HS, and PsO versus matched controls, and to examine sex-specific differences.
methodsUsing deidentified electronic health records from the international TriNetX network, we identified adults newly diagnosed with AD, HS, or PsO and matched each disease cohort 1:1 to control patients without the index dermatosis or prior mental disorders. Outcomes over 5 years were psychiatric evaluation, psychotherapy, and psychiatric medications (sedatives/hypnotics, anticonvulsants, antidepressants, antipsychotics). Risks were estimated with generalized linear models (risk ratios (RRs)) and Cox models (hazard ratios (HRs)), with sex-stratified analyses.
resultsAfter matching, the study included 447,821 AD pairs, 123,443 HS pairs, and 443,598 PsO pairs with balanced demographics and comorbidities. All dermatoses showed higher utilization than controls. In AD, psychotherapy displayed the largest relative increase (RR≈3.0); psychiatric evaluation and treatment were also elevated (RRs ≈2.6 and ≈1.35). In HS, risks were higher for psychiatric evaluation, psychotherapy, and especially psychiatric pharmacotherapy (RR ≈1.75). In PsO, psychiatric evaluation, psychotherapy, and psychiatric treatment were all increased (RRs ≈1.9, ≈1.9, and ≈1.34, respectively). Sex-stratified analyses showed women with AD had greater risks across all outcomes; in HS, only psychiatric pharmacotherapy was higher in women; in PsO, men had slightly higher pharmacotherapy use.
conclusionsAdults with AD, HS, and PsO have substantially greater psychiatric and psychological care utilization than matched controls, with meaningful sex differences. Findings support integrated, multidisciplinary management that proactively addresses mental health alongside dermatologic treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.